---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-11T17:44:47.308011'
end_time: '2026-01-11T17:51:19.742543'
duration_seconds: 392.43
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: OLIG2
  gene_symbol: OLIG2
  uniprot_accession: Q13516
  protein_description: 'RecName: Full=Oligodendrocyte transcription factor 2; Short=Oligo2;
    AltName: Full=Class B basic helix-loop-helix protein 1; Short=bHLHb1; AltName:
    Full=Class E basic helix-loop-helix protein 19; Short=bHLHe19; AltName: Full=Protein
    kinase C-binding protein 2; AltName: Full=Protein kinase C-binding protein RACK17;'
  gene_info: Name=OLIG2; Synonyms=BHLHB1, BHLHE19, PRKCBP2, RACK17;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: bHLH_dom. (IPR011598); bHLH_transcription_factors. (IPR050359);
    HLH_DNA-bd_sf. (IPR036638); Olig2_bHLH. (IPR032658); HLH (PF00010)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 18
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q13516
- **Protein Description:** RecName: Full=Oligodendrocyte transcription factor 2; Short=Oligo2; AltName: Full=Class B basic helix-loop-helix protein 1; Short=bHLHb1; AltName: Full=Class E basic helix-loop-helix protein 19; Short=bHLHe19; AltName: Full=Protein kinase C-binding protein 2; AltName: Full=Protein kinase C-binding protein RACK17;
- **Gene Information:** Name=OLIG2; Synonyms=BHLHB1, BHLHE19, PRKCBP2, RACK17;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** bHLH_dom. (IPR011598); bHLH_transcription_factors. (IPR050359); HLH_DNA-bd_sf. (IPR036638); Olig2_bHLH. (IPR032658); HLH (PF00010)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "OLIG2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'OLIG2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **OLIG2** (gene ID: OLIG2, UniProt: Q13516) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q13516
- **Protein Description:** RecName: Full=Oligodendrocyte transcription factor 2; Short=Oligo2; AltName: Full=Class B basic helix-loop-helix protein 1; Short=bHLHb1; AltName: Full=Class E basic helix-loop-helix protein 19; Short=bHLHe19; AltName: Full=Protein kinase C-binding protein 2; AltName: Full=Protein kinase C-binding protein RACK17;
- **Gene Information:** Name=OLIG2; Synonyms=BHLHB1, BHLHE19, PRKCBP2, RACK17;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** bHLH_dom. (IPR011598); bHLH_transcription_factors. (IPR050359); HLH_DNA-bd_sf. (IPR036638); Olig2_bHLH. (IPR032658); HLH (PF00010)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "OLIG2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'OLIG2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **OLIG2** (gene ID: OLIG2, UniProt: Q13516) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan summary
- Verified identity: OLIG2 (UniProt Q13516) is the human basic helix–loop–helix (bHLH) transcription factor “Oligodendrocyte transcription factor 2,” also referred to as BHLHB1/bHLHe19; literature consistently treats OLIG2 as a CNS-restricted lineage TF for oligodendroglia, aligning with UniProt’s bHLH domain annotations. No symbol ambiguity was detected in the recent literature surveyed. (Szu 2023, Frontiers in Neuroscience, May 2023; https://doi.org/10.3389/fnins.2023.1129434) (szu2023biologicalfunctionsof pages 8-9, szu2023biologicalfunctionsof pages 7-8)

Research report: OLIG2 (human; UniProt Q13516)

1) Key concepts and definitions with current understanding
- Identity and domains: OLIG2 is a Class B/E basic helix–loop–helix transcription factor that binds E-box DNA motifs to regulate lineage programs. It marks oligodendroglial lineage cells in development and adult CNS and is widely expressed in diffuse gliomas. Its bHLH domain and DNA-binding function match the UniProt domain annotations provided. (Frontiers in Neuroscience; May 2023; https://doi.org/10.3389/fnins.2023.1129434) (szu2023biologicalfunctionsof pages 7-8)
- Cellular localization: OLIG2 protein is primarily nuclear in oligodendroglial cells and gliomas, supporting a role as a transcriptional regulator. Anti-human OLIG2 antibodies are widely used in immunohistochemistry (IHC) with nuclear staining patterns in gliomas. (Frontiers in Neuroscience; May 2023; https://doi.org/10.3389/fnins.2023.1129434) (szu2023biologicalfunctionsof pages 3-4, szu2023biologicalfunctionsof pages 8-8)
- Core molecular functions: OLIG2 orchestrates neuron–glia fate decisions and is required for oligodendrocyte precursor cell (OPC) specification and oligodendrocyte differentiation. Mechanistically, OLIG2 acts as a lineage- and cell-cycle regulator, repressing p21 and antagonizing p53 acetylation to support replication competence in neural stem/progenitor cells and malignant glioma. (Frontiers in Neuroscience; May 2023; https://doi.org/10.3389/fnins.2023.1129434) (szu2023biologicalfunctionsof pages 4-5)
- Partner transcription factors and complexes: Functional partners include ASCL1, SOX10, and NKX2.2 in the oligodendroglial gene regulatory network. In glioblastoma (GBM), OLIG2 and ASCL1 co-occupy each other’s loci and extensively co-bind downstream targets, jointly shaping tumor cell states and migration. (Nature Communications; Nov 2024; https://doi.org/10.1038/s41467-024-54750-9) (myers2024transcriptionfactorsascl1 pages 1-2, myers2024transcriptionfactorsascl1 pages 14-15)
- Upstream signaling pathways: OLIG2 is induced by Sonic hedgehog (Shh) and participates in cross-talk with FGF and EGFR receptor tyrosine kinase signaling; Notch activity is linked to nucleocytoplasmic dynamics of OLIG2 in reactive astrocytes and to stem-like behavior in gliomas. (Frontiers in Neuroscience; May 2023; https://doi.org/10.3389/fnins.2023.1129434) (szu2023biologicalfunctionsof pages 3-4, szu2023biologicalfunctionsof pages 4-5, szu2023biologicalfunctionsof pages 8-8)
- Post-translational regulation: Phosphorylation of OLIG2 modulates intranuclear compartmentalization and fate outcomes (e.g., a serine-rich N-terminal motif; phosphorylation state linked to proliferation vs differentiation decisions). Notch-dependent control of nucleocytoplasmic translocation has been reported in astroglial contexts. (Frontiers in Neuroscience; May 2023; https://doi.org/10.3389/fnins.2023.1129434) (szu2023biologicalfunctionsof pages 8-9, szu2023biologicalfunctionsof pages 8-8)

2) Recent developments and latest research (prioritized 2023–2024)
- ASCL1–OLIG2 co-regulation in GBM initiation and heterogeneity: A 2024 Nature Communications study demonstrates that ASCL1 and OLIG2 are redundantly required for GBM initiation in a mouse model; they bind each other’s loci and share extensive genomic targets in GBM. ChIP analysis shows OLIG2 overlaps with over 90% of 13,457 ASCL1 peaks, and ~98% of ASCL1 target genes are also OLIG2 targets; motif analysis identifies enriched E-boxes with GC cores. Single-cell RNA-seq reveals high ASCL1 level specifies migratory NSC/astrocyte-like tumor states, while OLIG2 is necessary for efficient activation of oligodendrocyte lineage programs. URL: https://doi.org/10.1038/s41467-024-54750-9 (published Nov 2024). (myers2024transcriptionfactorsascl1 pages 1-2, myers2024transcriptionfactorsascl1 pages 14-15)
- Lineage and receptor signaling plasticity around OLIG2: Contemporary summaries emphasize OLIG2’s role in reciprocal shifts between PDGFRA and EGFR signaling axes and its control over replication competence in glioma stem-like cells, consolidating a picture of OLIG2 as a linchpin for proneural/OPC-like programs. URL: https://doi.org/10.3389/fnins.2023.1129434 (May 2023). (szu2023biologicalfunctionsof pages 7-8, szu2023biologicalfunctionsof pages 4-5)
- Spatial niche and chromatin context (forward-looking): Spatial epigenomic analyses propose small, localized OPC-like niches with OLIG2/OPC programs embedded within larger mesenchymal-like niches, with short- and long-range signaling shaping cell-state equilibria (preprint 2025 for context). URL: https://doi.org/10.1101/2025.05.09.653178 (posted May 14, 2025). While insightful for OLIG2-associated OPC-like states, this is preprint-stage beyond 2024. (kint2025spatialepigenomicniches pages 20-22)

3) Current applications and real-world implementations
- Diagnostic utility (IHC): OLIG2 is a routine IHC marker in neuropathology to identify oligodendroglial lineage and diffuse gliomas, typically with strong nuclear staining; it is incorporated into diagnostic panels to distinguish glial tumors and assess lineage composition. Earlier pathology series and reviews consistently report high specificity and broad coverage across diffuse gliomas. (Frontiers in Neuroscience; May 2023; https://doi.org/10.3389/fnins.2023.1129434) (szu2023biologicalfunctionsof pages 3-4, szu2023biologicalfunctionsof pages 8-8)
- Research and translational targeting: Small-molecule strategies that disrupt OLIG2 dimerization/activity (e.g., reported CT-179) have shown reductions in OLIG2+ tumor cells and survival benefits in preclinical models. Given OLIG2’s integration with Shh/EGFR/Notch networks and its repression of p53 acetylation/p21, pathway-combination strategies are under consideration in preclinical research. (Frontiers in Neuroscience; May 2023; https://doi.org/10.3389/fnins.2023.1129434) (szu2023biologicalfunctionsof pages 4-5)

4) Expert opinions and analysis from authoritative sources
- Consensus from a 2023 peer-reviewed review: OLIG2 is a central lineage TF coupling neuron–glia fate choice and driving oligodendrogenesis; in cancer, OLIG2 sustains proliferation, opposes p53-mediated damage responses, and is broadly expressed in diffuse gliomas, nominating OLIG2 as both a diagnostic marker and therapeutic target. (Frontiers in Neuroscience; May 2023; https://doi.org/10.3389/fnins.2023.1129434) (szu2023biologicalfunctionsof pages 7-8, szu2023biologicalfunctionsof pages 4-5, szu2023biologicalfunctionsof pages 8-8)
- 2024 primary mechanistic evidence: The ASCL1–OLIG2 axis is now quantitatively mapped genome-wide in GBM, providing compelling evidence that OLIG2 is required for oligodendrocyte-lineage gene activation and that co-regulation with ASCL1 controls state composition, invasive properties, and initiation. These data refine models of OLIG2’s role beyond development into tumor ecology and therapeutic vulnerabilities. (Nature Communications; Nov 2024; https://doi.org/10.1038/s41467-024-54750-9) (myers2024transcriptionfactorsascl1 pages 1-2, myers2024transcriptionfactorsascl1 pages 14-15)

5) Relevant statistics and data (recent)
- Genomic co-occupancy and target sharing (GBM): OLIG2 overlaps with >90% of ASCL1 ChIP peaks (of 13,457 peaks) and ~98% of ASCL1 target genes are also OLIG2 targets; among 1,580 TCGA-correlated genes, 841 are direct shared targets (with ~40% nuclear-function and ~7% cell-cycle gene enrichments). Publication: Nov 2024; URL: https://doi.org/10.1038/s41467-024-54750-9. (myers2024transcriptionfactorsascl1 pages 1-2)
- Immunophenotyping and lineage composition: Single-cell and IHC observations situate OLIG2 as a principal marker of OPC-like/proneural programs; examples in 2024 experiments report shifts in SOX10+ and OLIG2+ fractions depending on ASCL1/OLIG2 perturbation, consistent with OLIG2’s necessity for efficient activation of oligodendrocyte-lineage genes. Publication: Nov 2024; URL: https://doi.org/10.1038/s41467-024-54750-9. (myers2024transcriptionfactorsascl1 pages 14-15)
- Developmental and cancer pathway linkages: Quantitative associations between Shh pathway activity and OLIG2 expression, and functional links to EGFR/Notch signaling, are consolidated in 2023 review summaries and primary references therein. Publication: May 2023; URL: https://doi.org/10.3389/fnins.2023.1129434. (szu2023biologicalfunctionsof pages 3-4, szu2023biologicalfunctionsof pages 4-5)

Functional annotation synthesis
- Primary function: OLIG2 is a nuclear bHLH transcription factor that binds E-box motifs to specify and maintain oligodendrocyte lineage programs, promote OPC specification and differentiation, and regulate replication competence and stress responses by repressing p21 and antagonizing p53 acetylation. Function is modulated by phosphorylation and upstream Shh/Notch/EGFR pathways, and is enacted in cooperation with TFs such as ASCL1, SOX10, and NKX2.2. (Frontiers in Neuroscience; May 2023; https://doi.org/10.3389/fnins.2023.1129434; Nature Communications; Nov 2024; https://doi.org/10.1038/s41467-024-54750-9) (szu2023biologicalfunctionsof pages 4-5, szu2023biologicalfunctionsof pages 7-8, myers2024transcriptionfactorsascl1 pages 1-2)
- Cellular context and localization: OLIG2 acts in the nucleus of OPCs and oligodendrocytes, as well as in OLIG2-positive tumor cells within gliomas. (Frontiers in Neuroscience; May 2023; https://doi.org/10.3389/fnins.2023.1129434) (szu2023biologicalfunctionsof pages 3-4)
- Pathway placement and disease relevance: In development, Shh and cooperating pathways induce OLIG2 to drive ventral forebrain/spinal OPC programs; in gliomas, OLIG2 anchors OPC-like/proneural states and contributes to growth, therapy resistance, and cell-state plasticity. The 2024 ASCL1–OLIG2 co-binding map provides a mechanistic bridge from lineage biology to glioma initiation and heterogeneity. (Frontiers in Neuroscience; May 2023; https://doi.org/10.3389/fnins.2023.1129434; Nature Communications; Nov 2024; https://doi.org/10.1038/s41467-024-54750-9) (szu2023biologicalfunctionsof pages 7-8, myers2024transcriptionfactorsascl1 pages 1-2, myers2024transcriptionfactorsascl1 pages 14-15)

Notes on verification and ambiguity
- The gene symbol OLIG2 in the cited literature consistently refers to the human CNS bHLH transcription factor with oligodendroglial-lineage roles, matching UniProt Q13516. Core domain architecture (bHLH) and functional annotations align with UniProt, and no conflicting gene identifications were encountered in recent sources. (Frontiers in Neuroscience; May 2023; https://doi.org/10.3389/fnins.2023.1129434) (szu2023biologicalfunctionsof pages 7-8)

References (URLs and dates)
- Szu JI, Tsigelny IF, Wojcinski A, Kesari S. Biological functions of the Olig gene family in brain cancer and therapeutic targeting. Frontiers in Neuroscience. 2023-05. URL: https://doi.org/10.3389/fnins.2023.1129434 (szu2023biologicalfunctionsof pages 8-9, szu2023biologicalfunctionsof pages 3-4, szu2023biologicalfunctionsof pages 4-5, szu2023biologicalfunctionsof pages 7-8, szu2023biologicalfunctionsof pages 8-8)
- Myers BL, Brayer KJ, Paez-Beltran LE, et al. Transcription factors ASCL1 and OLIG2 drive glioblastoma initiation and co-regulate tumor cell types and migration. Nature Communications. 2024-11. URL: https://doi.org/10.1038/s41467-024-54750-9 (myers2024transcriptionfactorsascl1 pages 1-2, myers2024transcriptionfactorsascl1 pages 14-15)
- Contextual/preprint beyond 2024: Kint S, Younes ST, Bao S, et al. Spatial epigenomic niches underlie glioblastoma cell state plasticity. bioRxiv. 2025-05-14. URL: https://doi.org/10.1101/2025.05.09.653178 (kint2025spatialepigenomicniches pages 20-22)
- Additional context compilation (OLIG2 in lineage fate and gliomagenesis): Tian Y, et al. Orchestrating the acquisition of OPC vs interneuron fates through Olig1/2 during mammalian cortical gliogenesis and gliomagenesis. bioRxiv. 2024-11. URL: https://doi.org/10.1101/2024.11.11.623106 (tian2024orchestratingtheacquisition pages 32-37)


References

1. (szu2023biologicalfunctionsof pages 8-9): Jenny I. Szu, Igor F. Tsigelny, Alexander Wojcinski, and Santosh Kesari. Biological functions of the olig gene family in brain cancer and therapeutic targeting. Frontiers in Neuroscience, May 2023. URL: https://doi.org/10.3389/fnins.2023.1129434, doi:10.3389/fnins.2023.1129434. This article has 18 citations and is from a peer-reviewed journal.

2. (szu2023biologicalfunctionsof pages 7-8): Jenny I. Szu, Igor F. Tsigelny, Alexander Wojcinski, and Santosh Kesari. Biological functions of the olig gene family in brain cancer and therapeutic targeting. Frontiers in Neuroscience, May 2023. URL: https://doi.org/10.3389/fnins.2023.1129434, doi:10.3389/fnins.2023.1129434. This article has 18 citations and is from a peer-reviewed journal.

3. (szu2023biologicalfunctionsof pages 3-4): Jenny I. Szu, Igor F. Tsigelny, Alexander Wojcinski, and Santosh Kesari. Biological functions of the olig gene family in brain cancer and therapeutic targeting. Frontiers in Neuroscience, May 2023. URL: https://doi.org/10.3389/fnins.2023.1129434, doi:10.3389/fnins.2023.1129434. This article has 18 citations and is from a peer-reviewed journal.

4. (szu2023biologicalfunctionsof pages 8-8): Jenny I. Szu, Igor F. Tsigelny, Alexander Wojcinski, and Santosh Kesari. Biological functions of the olig gene family in brain cancer and therapeutic targeting. Frontiers in Neuroscience, May 2023. URL: https://doi.org/10.3389/fnins.2023.1129434, doi:10.3389/fnins.2023.1129434. This article has 18 citations and is from a peer-reviewed journal.

5. (szu2023biologicalfunctionsof pages 4-5): Jenny I. Szu, Igor F. Tsigelny, Alexander Wojcinski, and Santosh Kesari. Biological functions of the olig gene family in brain cancer and therapeutic targeting. Frontiers in Neuroscience, May 2023. URL: https://doi.org/10.3389/fnins.2023.1129434, doi:10.3389/fnins.2023.1129434. This article has 18 citations and is from a peer-reviewed journal.

6. (myers2024transcriptionfactorsascl1 pages 1-2): Bianca L. Myers, Kathryn J. Brayer, Luis E. Paez-Beltran, Estrella Villicana, Matthew S. Keith, Hideaki Suzuki, Jessie Newville, Rebekka H. Anderson, Yunee Lo, Conner M. Mertz, Rahul K. Kollipara, Mark D. Borromeo, Q. Richard Lu, Robert M. Bachoo, Jane E. Johnson, and Tou Yia Vue. Transcription factors ascl1 and olig2 drive glioblastoma initiation and co-regulate tumor cell types and migration. Nature Communications, Nov 2024. URL: https://doi.org/10.1038/s41467-024-54750-9, doi:10.1038/s41467-024-54750-9. This article has 28 citations and is from a highest quality peer-reviewed journal.

7. (myers2024transcriptionfactorsascl1 pages 14-15): Bianca L. Myers, Kathryn J. Brayer, Luis E. Paez-Beltran, Estrella Villicana, Matthew S. Keith, Hideaki Suzuki, Jessie Newville, Rebekka H. Anderson, Yunee Lo, Conner M. Mertz, Rahul K. Kollipara, Mark D. Borromeo, Q. Richard Lu, Robert M. Bachoo, Jane E. Johnson, and Tou Yia Vue. Transcription factors ascl1 and olig2 drive glioblastoma initiation and co-regulate tumor cell types and migration. Nature Communications, Nov 2024. URL: https://doi.org/10.1038/s41467-024-54750-9, doi:10.1038/s41467-024-54750-9. This article has 28 citations and is from a highest quality peer-reviewed journal.

8. (kint2025spatialepigenomicniches pages 20-22): Sam Kint, Subhi Talal Younes, Shuozhen Bao, Gretchen Long, David Wouters, Erin Stephenson, Xing Lou, Mei Zhong, Di Zhang, Graham Su, Archibald Enninful, Mingyu Yang, Huey-Miin Chen, Katrina Ellestad, Colleen Anderson, Jennifer Moliterno, John Kelly, Jennifer A Chan, Alejandro Sifrim, Jiangbing Zhou, Ana Nikolic, Rong Fan, and Marco Gallo. Spatial epigenomic niches underlie glioblastoma cell state plasticity. bioRxiv, May 2025. URL: https://doi.org/10.1101/2025.05.09.653178, doi:10.1101/2025.05.09.653178. This article has 4 citations and is from a poor quality or predatory journal.

9. (tian2024orchestratingtheacquisition pages 32-37): Yu Tian, Ziwu Wang, Feihong Yang, Wen Zhang, Jialin Li, Lin Yang, Tongye Fu, Wenhui Zheng, Zhejun Xu, Tong Ma, Yan You, Xiaosu Li, Jiangang Song, Yunli Xie, Zhengang Yang, and Zhuangzhi Zhang. Orchestrating the acquisition of oligodendrocyte precursor cell versus olfactory bulb interneuron fates through olig1/2 during mammalian cortical gliogenesis and gliomagenesis. bioRxiv, Nov 2024. URL: https://doi.org/10.1101/2024.11.11.623106, doi:10.1101/2024.11.11.623106. This article has 2 citations and is from a poor quality or predatory journal.

## Citations

1. szu2023biologicalfunctionsof pages 7-8
2. szu2023biologicalfunctionsof pages 4-5
3. kint2025spatialepigenomicniches pages 20-22
4. szu2023biologicalfunctionsof pages 3-4
5. tian2024orchestratingtheacquisition pages 32-37
6. szu2023biologicalfunctionsof pages 8-9
7. szu2023biologicalfunctionsof pages 8-8
8. https://doi.org/10.3389/fnins.2023.1129434
9. https://doi.org/10.1038/s41467-024-54750-9
10. https://doi.org/10.1101/2025.05.09.653178
11. https://doi.org/10.1038/s41467-024-54750-9.
12. https://doi.org/10.3389/fnins.2023.1129434.
13. https://doi.org/10.3389/fnins.2023.1129434;
14. https://doi.org/10.1101/2024.11.11.623106
15. https://doi.org/10.3389/fnins.2023.1129434,
16. https://doi.org/10.1038/s41467-024-54750-9,
17. https://doi.org/10.1101/2025.05.09.653178,
18. https://doi.org/10.1101/2024.11.11.623106,